ZJJF(SH:600668)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was CNY 68,344.55 million, a decrease of 17.58% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was CNY 1,681.09 million, down 58.58% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,144.74 million, a decline of 68.57% compared to the previous year[5]. - Basic and diluted earnings per share for Q3 2023 were CNY 0.0489, reflecting a decrease of 58.58% year-on-year[6]. - The decline in net profit was primarily attributed to decreased sales and gross margins in the pharmaceutical and cement product segments[10]. - Total operating revenue for the first three quarters of 2023 was ¥2,064,631,835.35, a decrease of 20.3% compared to ¥2,592,003,944.26 in the same period of 2022[20]. - Net profit for Q3 2023 was ¥128,529,994.42, a decline of 43.3% from ¥226,555,624.24 in Q3 2022[21]. - Earnings per share for Q3 2023 was ¥0.37, down from ¥0.54 in Q3 2022[22]. - The total comprehensive income for Q3 2023 was ¥100,923,933.98, compared to ¥102,563,584.37 in Q3 2022[22]. Cash Flow and Assets - The cash flow from operating activities showed a net decrease of 86.41%, amounting to CNY 5,566.51 million[6]. - The net cash flow from operating activities for the first three quarters of 2023 was ¥55.67 million, a significant decline of 86.4% from ¥409.60 million in the first three quarters of 2022[26]. - The company's total assets as of Q3 2023 were ¥7,145,466,349.80, down from ¥7,320,603,423.01 in the previous year[19]. - Total assets at the end of Q3 2023 were CNY 714,546.63 million, a decrease of 2.39% from the end of the previous year[6]. - Current assets totaled CNY 1,241,722,248.95, down from CNY 1,392,257,613.25 in the previous year[17]. - Cash and cash equivalents decreased to CNY 248,804,783.02 from CNY 373,161,388.05[16]. - The total cash and cash equivalents at the end of Q3 2023 were ¥243.65 million, a decrease from ¥283.59 million at the end of Q3 2022[27]. Liabilities and Equity - Total liabilities as of Q3 2023 amounted to ¥1,589,597,734.70, a decrease from ¥1,735,327,038.49 in the previous year[19]. - The total equity attributable to shareholders was CNY 518,603.15 million, showing a slight increase of 0.01% compared to the previous year[6]. - Total equity attributable to shareholders was ¥5,186,031,455.49, slightly up from ¥5,185,605,324.78 year-over-year[19]. Investments and Expenses - Research and development expenses for the first three quarters of 2023 were ¥84,057,891.93, a decrease from ¥90,929,570.71 in the same period of 2022[20]. - The company reported an investment income of ¥60,752,196.45 for the first three quarters of 2023, compared to a loss of ¥20,304,995.08 in the same period of 2022[20]. - The cash received from investment income in Q3 2023 was ¥25.75 million, a decrease of 69.7% from ¥85.13 million in Q3 2022[26]. Shareholder Information - The largest shareholder, Jinhua Tongji State-owned Assets Investment Co., Ltd., holds 16.15% of shares[14]. - The company has not disclosed any significant new product developments or market expansion strategies in the current report[15].